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ABSTRACT
Objectives: The study investigated (1) the association
between comorbidity and multidrug prescribing
compared with the index condition, and (2) the
association between vascular comorbidity and non-
vascular condition key drug prescribing.
Design: Cross-sectional study linking anonymised
computer consultations with prescription records for a
2-year time period.
Setting: 11 general practices in North Staffordshire,
England.
Participants: Study groups aged 40 years and over
(N=12 875). Within six conditions, comorbid group
with the other five conditions was compared with an
‘alone’ group without them. Additionally, how the
‘vascular’ (one of diabetes, cardiovascular disease and
cerebrovascular disease) comorbidity influenced
chronic obstructive pulmonary disease (COPD),
osteoarthritis (OA) or depression drug prescribing was
investigated.
Outcome measures: Based on the British National
Formulary, five main drug chapters constituted a
measure of drug counts, with low count as 2 or less
and high multidrug count as 3 or more. Key drugs
prescribed for COPD, OA and depression were derived
from guidelines.
Results: The adjusted associations between the
comorbid groups and higher multidrug count
compared with their respective ‘alone’ group were:
odds ratio (OR) 7.1 (95% CI 5.6 to 9.0) for
depression, OR 5.4 (95% CI 4.6 to 6.3) for
cardiovascular disease, OR 3.7 (95% CI 2.8 to 5.0) for
cerebrovascular disease, OR 3.6 (95% CI 3.1 to 4.3) for
OA, OR 3.5 (95% CI 3.0 to 4.2) for diabetes and OR 3.2
(95% CI 2.6 to 4.0) for COPD. In COPD, vascular
comorbidity was associated with a significant reduction
in key COPD drug treatments (adjusted OR 0.6 (95%
CI 0.4 to 0.8). In depression, vascular comorbidity was
associated with a reduction in key depression drug
treatments (OR 0.6 (95% CI 0.4 to 0.7)).
Conclusions: Our findings show that multidrug
prescribing for different body systems is higher with
comorbidity and may be associated with lower likelihood
of prescribing for specific conditions. Further research is
required on whether multidrug prescribing influences
the outcomes of care for chronic conditions.
INTRODUCTION
Many older people experience two or more
morbidities at the same time which is
deﬁned as multimorbidity, and within this
comorbidity is deﬁned as other co-occurring
diseases in the same individual with an index
condition.1 2 These are important concepts
as the experience of multiple conditions at
the same time may inﬂuence the progression
and treatment of an index condition.
Current evidence of the overall implications
of chronic diseases has shown that this phe-
nomenon is associated with adverse health,
increased healthcare utilisation and
increased mortality.3–5 Although the health
impact of chronic disease comorbidity has
been studied, there have been few studies on
how chronic diseases comorbidity might
inﬂuence drug use and related clinical deci-
sions, especially in general practice. This is a
signiﬁcant evidence gap despite the fact that
Strengths and limitations of this study
▪ The study was based on large-scale data linking
common chronic conditions from general prac-
tice populations to prescription data over a
2-year time period.
▪ The study highlights the innovative approach to
multidrug measurement which accounts for vas-
cular condition-specific drugs as well as sum-
marising non-vascular codrug therapy.
▪ The study provides the emergent approach to
investigating the influence of multidrug therapy
on potentially ‘optimal’ drug prescribing in
populations.
▪ The study uses a specific but limited number of
common chronic conditions to illustrate the
approach to linking comorbidity and multidrug
data within a single large region of the UK.
▪ The study used overall broad measures of drug
prescribing and further research is required to
understand the specific influence of multidrug
dose and duration on longer term outcomes.
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drug interventions feature routinely in many disease
guidelines. Currently, the model for managing chronic
diseases focuses on treating individual conditions, and
patients may on the one hand beneﬁt from the drug
treatment of each of their chronic conditions; however,
there is a risk of multiple drug therapy, side effects and
drug interactions which could in combination be
detrimental.6 7
Many national healthcare policies have developed fra-
meworks for chronic disease models of care and speciﬁc
guidelines for the optimal management of chronic dis-
eases. Examples include policy and guidelines for the
common conditions in the general population with dia-
betes, ischaemic heart disease, stroke, chronic obstruct-
ive airways disease and depression.8–12 In addition, these
guidelines are beginning to be adapted for the common
experience of comorbid conditions, particularly by older
people, for each of these individual conditions.13 Since
people with one or more chronic conditions are increas-
ing in number, this has increasingly brought in focus the
scale and quantity of multiple drug prescribing in
general populations. The key questions then become (1)
how does multiple drug prescribing for different systems
relate to the primary index condition and (2) how does
multiple drug prescribing escalate when populations
experience multiple conditions which might be directly
linked or occur by chance together. The cardiometa-
bolic diseases, such as hypertension, diabetes, heart
disease and cerebrovascular disease, share aetiology and
common drug treatment pathways, but it is still import-
ant to understand the scale of multiple drug therapy
that might be associated when these conditions co-occur
together in the same individual. Many chronic diseases
also have conditions which are related to mechanisms
other than pathophysiology. For example, other
common chronic conditions include chronic obstructive
airways disease and depression, and this epidemiology
provides the scale of multiple drug therapies when
co-occurring conditions might be unrelated.
In terms of the current evidence in this ﬁeld, much of
it has focused around ‘polypharmacy’ studies.14–16
However, while this might seem an appropriate broad
umbrella term, in research and clinical approaches, it
has often focused on arbitrarily chosen number of
drugs, and linked the term to either inappropriate pre-
scribing or associated adverse events in older popula-
tions.16 This lack of consensus deﬁned approach to this
problem has led to an argument for less ambiguous ter-
minology,17 and we propose that ‘multidrug’ therapy is
used to link in with the standard approach to two or
more conditions, which is ‘multimorbidity’. Within this
evidence, there is still a clear gap in how morbidity link
to drug prescribing, and whether comorbidity inﬂuences
the drug prescribing for an index disease.
In this study, the focus was on six common chronic
conditions in the general population, which included
diabetes mellitus, cardiovascular diseases, cerebrovascu-
lar diseases, chronic obstructive pulmonary diseases
(COPD), osteoarthritis (OA) and depression. The
choice of these chronic conditions for the purpose of
the study was based on a number of factors including
the epidemiology, especially prevalence of the diseases,
as well as aetiopathogenesis and impacts on quality of
life and psychological well-being. For example, while dia-
betes mellitus, coronary heart disease and cerebrovascu-
lar diseases have a common pathological basis of
causation (the ‘vascular group’), and often coexist in
one patient, they are also known to have high mortality
rates—hence the drive towards measures aimed at opti-
mising the management of these diseases.18 19 The
other three non-vascular chronic conditions—COPD,
OA and depression—are leading causes of morbidity,
high cost of care and psychological distress, respect-
ively.20–22 The rationale for our focus on few selected
common conditions was also to provide common
comorbidity combinations which are potentially treated
with drugs as a key intervention.
We investigated two separate issues using the selected
group of vascular and non-vascular conditions. First, we
wanted to investigate the relative multidrug prescribing
for each of six chosen index examples, comparing
comorbid groups with prescribing levels in the respect-
ive index groups. Second, we wanted to test whether vas-
cular comorbidity inﬂuenced key drug prescribing for
chosen conditions. The vascular group was likely to be
on similar multiple drugs, so the distinct hypothesis was
tested, that was drug prescribing in vascular conditions
overall may inﬂuence key drug prescribing in the indi-
vidual non-vascular conditions of COPD, OA or
depression.
METHODS
Design and study population
The cross-sectional study was conducted using two
linked databases on patients aged 40 years and over pre-
senting to general practice over a 2-year time period
(from 1 January 2002 to 31 December 2003). We wanted
to investigate what multidrug prescribing levels were
before a national UK performance-based incentive
(Quality outcomes Framework) was implemented to test
the associations between comorbidity and routine multi-
drug prescribing.
Settings
The clinical and prescription databases analysed were
derived from an anonymised computer-recorded consul-
tations from 11 general practices from the North
Staffordshire Keele GP research partnership. The part-
nership covers a range of practices covering varying socio-
economic groups within rural and urban areas and has
been involved in data collection over time for the
purpose of epidemiological studies. There is an ongoing
process of data validation to improve data quality, and
there is evidence that this measure improves data record-
ing by general practitioners (GPs) and their teams.23
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Chronic disease data
The Consultation in Primary Care Archive (CiPCA) data-
base focuses on the routinely collected morbidity
encounters in actual consultations and coded using a
standard clinical classiﬁcation (READ codes).24 Patients
who had a record of a disease-speciﬁc READ coded mor-
bidity of interest were included in the study and the
main codes were used with all associated ‘daughter
codes’. The main READ codes that were used to deﬁne
the chronic disease groups were: diabetes mellitus
(READ codes C10), cardiovascular diseases (ischaemic
heart disease (G3); heart failure (G58), excluding hyper-
tension), cerebrovascular diseases (G6), COPD (H30,
excluding asthma), OA (N05, excluding arthralgia) and
depression (E11, E20, Eu and excluding psychosis).
Comorbidity: definitions
There were two approaches to deﬁning comorbidity.
First, comorbidity was deﬁned as the presence of one of
the other ﬁve selected conditions. So using the diabetes
population as an example, the diabetes ‘index’ group
was deﬁned as diabetes ‘alone’ and without anyone of
the other ﬁve conditions, whereas diabetes ‘comorbid’
group was deﬁned as at least one of the other ﬁve condi-
tions. The index ‘alone’ group would also enable the
capture of the other morbidity that was outside of the
ones within the study. This deﬁnition was applied to
each of the six chronic conditions individually. Second,
in the vascular group, comorbidity was deﬁned separ-
ately as the individual and speciﬁc addition of COPD,
OA or depression, and irrespective of whether the latter
three occurred together.
Prescribed drug measure: overall multidrug count
definitions
The Prescriptions in Primary Care Archive (PiPCA) data-
base focuses on the routinely collected prescribed medi-
cations and which were coded using the British National
Formulary (BNF) classiﬁcation.25 The BNF consists of 15
main chapters based on the systems of the body, and
within which there are further subsections for speciﬁc
clinical indications. Only patients on repeat drug pre-
scriptions were selected for deﬁning measures because
this gives a better representation of multiple drugs used
on a long-term basis for the majority of patients with
chronic conditions.
Speciﬁc drug treatment chapters for the six chronic
diseases of interest in the study were identiﬁed and used
as a summary of multidrug counts. The BNF chapter for
cardiovascular and cerebrovascular drugs was under
BNF chapter 2, for COPD drugs under chapter 3, for
depression under chapter 4, for diabetes mellitus under
chapter 6 and for OA under chapters 4 and 10. This
means that overall, there were ﬁve main BNF chapters,
which could constitute a measure of drug counts of up
to a total of 5. The multidrug count deﬁnition in this
approach would then speciﬁcally relate to people
prescribed drugs from at least two or more of the ﬁve
chapters indicated.
Vascular comorbidity and drug prescribing for
non-vascular conditions
The key likelihood of receiving drug treatments for the
speciﬁc conditions of COPD, OA and depression in the
study population with vascular comorbidity was also
investigated. In this approach, the ‘vascular’ comorbidity
was deﬁned as the group any one of diabetes, cardiovas-
cular disease and cerebrovascular disease. The non-
vascular groups were then individually compared with
and without vascular comorbidity. For example, the
COPD group was compared with vascular comorbidity to
the COPD without vascular comorbidity, in relation to
the likelihood of receiving COPD-speciﬁc drug
treatment.
While the key drug treatments for COPD, OA and
depression can be examined in different ways such as
the use of speciﬁc drugs, or drug doses and duration of
drug therapy, we wanted to ﬁrst establish the simplest
likelihood of a patient given any one of the key group of
drugs for COPD, OA or depression. The group of drugs
derived from guidelines for COPD10 included broncho-
dilators, corticosteroids, inhaled steroids and oxygen
(BNF sections 3.1, 3.2, 3.5 and 3.6). The group of drugs
for OA26 included non-opioid analgesics, opioid analge-
sics, non-steroidal anti-inﬂammatories and Cox 2 inhibi-
tors (BNF sections 4.7.1, 4.7.2, 10.1.1 and 10.1.2.2). The
group of drugs for depression11 included hypnotics,
anxiolytics and antidepressants (BNF sections 4.1
and 4.3).
Analysis
The ﬁrst analysis was to describe the 2-year period preva-
lence of the ﬁve main BNF chapters in the speciﬁed
chronic disease population, with a focus on some of the
common drugs that were prescribed within each chapter
expressed as drug prevalence/10 000 population aged
40 years and over, and differences were assessed using χ2
tests. The ﬁve main chapter drug categories prevalence
is described by age, gender and deprivation status.
Deprivation was measured by the Index of Multiple
Deprivation (IMD) which is a composite score that is
linked to postal address codes.27 The IMD score was
categorised into the bottom 20% (most deprived),
middle 60% and the top 20% score (most afﬂuent).
For each of the six chronic conditions, associations
between the comorbid groups and higher multidrug
counts were compared with the respective reference
‘alone’ group. The ‘outcome’ of higher multidrug
therapy was deﬁned as 3 or more of the chapter counts
and compared with 2 counts or less. Associations using
logistic regression were expressed as ORs with 95% CIs,
and also included the ratios comparing prevalence of
each drug count category in the comorbid group com-
pared with the ‘alone’ group. Then for the vascular
group, associations between each of the comorbid group
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with COPD, OA or depression were compared with the
vascular ‘alone’ alone, and higher multidrug counts
were then estimated.
Finally, the data were analysed for the study deﬁned
optimal drug treatments for COPD, OA or depression.
Three study groups constructed were: COPD with at
least one of the vascular conditions; OA with at least one
of the vascular conditions and depression with at least
one of the vascular conditions. Each group was then
compared to their respective vascular group, for
example, COPD and vascular group compared with
COPD without a vascular condition, by the speciﬁc
optimal drug treatment. Association estimates using
logistic regression are presented as unadjusted and
adjusted ﬁgures with 95% CIs. Analyses were carried out
using SPSS V.17.0 statistical software.
RESULTS
Study population
In the study population of 12 875 aged 40 years and
over, the numbers of patients prescribed with cardiovas-
cular system drugs were 9384 (2-year time period preva-
lence 73%), respiratory system drugs were 2861 (22%),
non-opioid analgesia were 5395 (42%), antidepressants
were 3241 (25%), antidiabetic drugs were 2916 (23%)
and musculoskeletal system anti-inﬂammatory drugs
were 2143 (17%; table 1).
In terms of the sociodemographic distribution, older
patients aged 70 years and over and populations in the
top 20% most deprived status were signiﬁcantly more
likely to be prescribed all main drug categories, except
for the cardiovascular system (χ2 test for trend p<0.001).
For women compared with men, there was variation by
type of main drug category; the comparative 2-year
prevalence ﬁgures by gender were signiﬁcantly higher
for men compared with women for the cardiovascular
system drugs (76% vs 70%) and diabetes (26% vs 20%),
but similar for COPD (p=0.462). Prevalence ﬁgures
were lower for men compared with women for anxioly-
tics and antidepressants (49% vs 66%) and anti-
inﬂammatories (15% vs 18%; χ2 test p<0.001; table 2).
Individual chronic condition comorbidity and higher
multidrug counts
For all six speciﬁed chronic conditions, at lower drugs
counts of up to 2, the prevalence numbers were greater
for the individual groups without the other ﬁve
comorbid conditions compared with the numbers for
the individual conditions with comorbidity of other ﬁve
conditions (table 3). For the drug count of 2 different
chapters, the comorbid to ‘alone’ ratios ranged from
1.15 for the depression group to 0.5 for the diabetes
group. The prevalence ratios were highest for the multi-
drug count of 4, and these ranged from 13.7 for the
depression comorbid group to 2.3 for the diabetes
comorbid group.
Adjusting for age, gender and deprivation, the associa-
tions between the comorbid groups and higher multi-
drug count compared with their respective ‘alone’
group ordered by strength of association were: OR 7.1
(95% CI 5.6 to 9.0) for depression, OR 5.4 (95% CI 4.6
to 6.3) for cardiovascular disease, OR 3.7 (95% CI 2.8 to
5.0) for cerebrovascular disease, OR 3.6 (95% CI 3.1 to
4.3) for OA, OR 3.5 (95% CI 3.0 to 4.2) for diabetes
and OR 3.2 (95% CI 2.6 to 4.0) for COPD.
Vascular condition comorbidity and higher multidrug
counts
The prevalence ratios for the multidrug count of 5
ranged from 3.9 for vascular group comorbid with
OA to 1.9 for vascular group comorbid with COPD and
1.0 for the vascular group comorbid with depression
(table 4). Adjusting for age, gender and deprivation, the
associations between the comorbid groups and higher
multigroup count compared with their respective ‘alone’
group ordered by strength of association were: OR
4.6 (95% CI 3.8 to 5.7) for vascular group comorbid
with COPD, OR 3.2 (95% CI 2.6 to 3.9) for vascular
group comorbid with depression and OR 3.0 (95%
CI 2.6 to 3.5) for vascular group comorbid with OA.
Comorbid vascular conditions and optimal non-vascular
condition prescribing
The three speciﬁc non-vascular groups of COPD, OA
and depression were compared with comorbid vascular
conditions to without such vascular comorbidity in terms
of their respective optimal drug treatment (table 5).
Adjusting for age, gender and deprivation, the associ-
ation between the COPD and vascular comorbid groups
compared with their respective group without vascular
conditions showed a signiﬁcant reduction in optimal
COPD drug treatment with an OR of 0.6 (95% CI 0.4 to
0.8). Adjusting for age, gender and deprivation, the asso-
ciation between the depression and vascular comorbid
groups compared with their respective group without
vascular conditions showed a signiﬁcant reduction in
optimal depression drug treatment with an OR of 0.6
(95% CI 0.4 to 0.7). Adjusting for age, gender and
deprivation, the association between the OA and vascu-
lar comorbid groups compared with their respective
group without vascular conditions did not show a statis-
tically signiﬁcant reduction in optimal OA drug treat-
ment with an OR of 0.8 (95% CI 0.6 to 1.1).
DISCUSSION
Our ﬁndings from a large cross-sectional study of nearly
13 000 patients aged 40 years and over with one of six
speciﬁed and common chronic conditions showed the
scale of multidrug prescribing, which was higher in the
presence of comorbidity compared with the respective
index groups. While previous evidence has shown the
high levels of multiple drug prescribing,15 our study
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ﬁndings link the disease and comorbidity status to the
measure of multidrug prescribing for different systems.
Depending on whether the chronic conditions were
vascular (diabetes, cardiovascular or cerebrovascular) or
non-vascular (COPD, OA or depression), the higher
levels of multidrug prescribing varied. All six conditions
with comorbidity compared with their index condition
had much higher multidrug count, even adjusting for
age, gender and deprivation. The measure of multidrug
count was notably distinct by the use of ﬁve different
main drug chapter categories which were for different
body systems, which means that this ‘outcome’ was not
about multiple drug use for the same condition. For
example, a diabetic with a higher multidrug count of 4
or 5 in this study relates to different and distinct body
systems, and not to the different drugs under the same
chapter. The chronic condition of depression comorbid-
ity had the strongest strength of association with higher
multidrug counts, followed by cardiovascular disease
comorbidity, and the estimates of association for cere-
brovascular disease, OA and diabetes were similar. These
ﬁndings suggest that the index condition and associated
comorbidity may inﬂuence the range of multidrug pre-
scribing, and generates the interesting hypothesis that
potential variation in clinical outcomes of the index con-
ditions is as a result of underlying comorbid drug
prescribing.
The study also grouped the vascular-related conditions
to investigate the inﬂuence of non-vascular drug pre-
scribing compared with vascular conditions ‘alone’ (ie,
without any one of COPD, OA or depression). Again,
the adjusted associations were signiﬁcant, with vascular
comorbidity being associated with higher multi drug
counts compared with the respective ‘vascular index’
group. Here the clinical implication is that vascular
comorbidity in populations aged 40 years and over
might not only be associated with multiple vascular
drugs as routinely suggested by clinical guidelines28 but
Table 1 Prescribed drug prevalence by BNF main chapter and specific sections
BNF chapter
BNF
subsections BNF classification Drug examples Number
Drug
prevalence/
10 000†
2 Cardiovascular system 9384 7289
2.9 Antiplatelet drugs Aspirin, clopidogrel,
dipyridamole
5044 3918
2.8 Anticoagulants Warfarin 669 520
2.2 Diuretics Thiazide diuretics 4912 3815
2.4 β-blockers Bisoprolol 4034 3133
2.5 ACE inhibitors or ARB Ramipril, candesartan 4250 3301
2.6 nitrates, calcium
antagonists
GTN, amlodipine 4984 3817
2.12 Lipid regulating drugs Simvastatin 4894 3801
3 Respiratory system 2861 2222
3.1 Bronchodilators Salbutamol 2775 2155
3.2 Corticosteroids Beclomethasone 2140 1662
3.6 Oxygen NA 94 73
4 Central nervous system
drugs
7478 5808
4.7.1 Non-opioid analgesics Paracetamol 5395 4190
4.7.2 Opioid analgesics Codeine, tramadol 855 664
4.1 Hypnotics and anxiolytics Diazepam 1180 917
4.3 Selective serotonin
reuptake inhibitors
Tricyclic antidepressants
Fluoxetine, citalopram,
amitriptyline
3241 2517
6 Endocrine system 2916 2265
6.1.1 Insulin Insulin, humalog 632 491
6.1.2 Oral antidiabetic drugs Metformin, gliclazide 2334 1805
10 Musculoskeletal and
joint disease
2143 1664
10.1.1 Non-steroidal
anti-inflammatory drugs
Ibuprofen,
cyclooxygenase inhibitors
2143 1664
†Population refers to those with one of six chronic conditions (n = 12 875), which included hypertension, diabetes, coronary heart disease,
cerebrovascular disease, chronic obstructive pulmonary disease, osteoarthritis and depression; drug categories are based on the BNF
classification.
ACE, angiotensin-converting-enzyme; ARB, angiotensin II receptor blockers; BNF, British National Formulary; GTN, glyceryl trinitrate;
NA, not applicable.
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by a range of conditions such as comorbidity of COPD,
OA or depression. It is possible that these conditions
and the drug treatments for them may also in the end
inﬂuence the health and healthcare outcomes of the
index vascular conditions.29
In terms of the inﬂuence of comorbidity on key drug
prescribing, our study ﬁndings show that vascular
comorbidity in COPD and depression is associated with
lower likelihood of drug prescribing for the respective
conditions of COPD and depression. Similar ﬁndings,
particularly for suboptimal depression drug treatment,
when depression is comorbid with chronic disease have
been shown previously.30 31 However, such ﬁndings for
OA were not found, and here it is possible that the study
deﬁnition of analgesia was too broad, as analgesia use
covers a range of other painful conditions, in addition
to OA. Although the key drug deﬁnition was simple and
broad, our study ﬁndings seem to suggest that comorbid-
ity does inﬂuence drug prescribing for speciﬁc condi-
tions. Whether this is due to some kind of therapeutic
inertia or is due to GPs’ reasoned consideration of
drug–drug and drug–disease interactions and the overall
Table 2 Sociodemographic characteristics of the main drug categories
Factor
Total
numbers
Main drug categories
Cardiovascular
system
Respiratory
system
Central
nervous
system
Endocrine
system
Musculoskeletal
system
Age (years)
40–54 2738 1257 (46) 441 (16) 1447 (53) 555 (20) 378 (14)
55–69 4963 3712 (75) 1131 (23) 2694 (54) 1250 (25) 1003 (20)
70–84 4459 3807 (85) 1154 (26) 2824 (63) 1010 (23) 703 (16)
85 and over 715 608 (85) 135 (19) 513 (72) 101 (14) 59 (8)
Gender
Women 6896 4813 (70) 1510 (22) 4528 (66) 1351 (20) 1260 (18)
Men 5979 4571 (76) 1351 (23) 2950 (49) 1565 (26) 883 (15)
Deprivation*
Deprived status 2609 1952 (75) 780 (30) 1705 (65) 695 (27) 474 (18)
Middle status 7228 5308 (73) 1538 (21) 4184 (58) 1616 (22) 1223 (17)
Affluent status 2203 1584 (72) 354 (16) 1185 (54) 419 (19) 377 (17)
*Deprivation measured by Index of Multiple of Deprivation, figures in brackets refer to the percentage of each study factor subgroup.
Table 3 Associations between individual study groups and higher multidrug counts
Conditions
Multidrug number/10 000 population
Adjusted OR (95% CI)0 1 2 3 4 5
Diabetes ‘alone’* 239 1178 4332 3120 1021 110 1.0
Diabetes comorbidity 58 492 2208 4523 2353 366 3.50 (3.0 to 4.2)
Prevalence ratio† 0.2 0.4 0.5 1.5 2.3 3.3
CHD ‘alone’* 148 4057 4248 1372 160 16 1.0
CHD comorbidity 36 1027 3973 3516 1327 121 5.35 (4.6 to 6.3)
Prevalence ratio† 0.2 0.3 0.9 2.6 8.3 7.6
CVD ‘alone’* 688 4087 3848 1306 70 0 1.0
CVD comorbidity 41 1745 4251 3224 678 62 3.70 (2.8 to 5.0)
Prevalence ratio† 0.1 0.4 1.1 2.5 9.7 NA
COPD ‘alone’* 940 2487 3496 2726 350 0 1.0
COPD comorbidity 189 946 2855 4117 1751 142 3.22 (2.6 to 4.0)
Prevalence ratio† 0.20 0.4 0.8 1.5 5.00 NA
OA ‘alone’* 1378 2786 3722 1854 256 5 1.0
OA comorbidity 174 1260 3550 3420 1325 271 3.64 (3.1 to 4.3)
Prevalence ratio† 0.1 0.5 1.0 1.8 5.2 54
Depression ‘alone’* 1912 4140 3093 776 79 0 1.0
Depression comorbidity 325 1422 3555 3555 1082 62 7.11 (5.6 to 9.0)
Prevalence ratio† 0.17 0.34 1.15 4.58 13.7 NA
*Alone—people with disease alone and none of the other five morbidities, comorbidity is 1 or more of other five study morbidities.
†Prevalence ratio=2-year drug count prevalence in the comorbid group/2-year drug count prevalence in the disease alone group; adjusted for
age, gender and deprivation and estimates are with the ‘outcome’ of higher drug count (3–4 combined) compared to lower drug counts (2 or
less)
CHD, coronary heart disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; NA, not applicable; OA,
osteoarthritis.
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well-being of the patient is the important question raised
by the ﬁndings.
The approach taken to look at speciﬁc groups and six
common conditions was based on a combination of clin-
ical rationale and feasibility. While, one could have inves-
tigated any number of combinations of the six
conditions, the better and preferred approach taken was
to group conditions ﬁrst at the ‘vascular’ level. As high-
lighted earlier, diabetes, ischaemic heart disease and
cerebrovascular disease have shared pathogenesis and
there may be overlapping of drug treatments. However,
the ‘non-vascular’ group constitutes individual chronic
conditions with distinct and unrelated drug treatments.
This approach enabled comorbidity deﬁnitions based on
(1) group-level, that is, vascular comorbidity with one of
the non-vascular conditions and (2) counts, that is,
number of other conditions for each of the six index
groups. The study focus was also on comorbidity and
further research is also required on how multimorbidity,
deﬁned as two or more conditions, inﬂuences the
overall prescribing of multiple drugs and when the unit
of analysis for outcome is not the disease but the argu-
ably more important patient-centred outcomes.
The large scale study of speciﬁed chronic diseases was
conducted using an anonymised database for a 2-year
time period. In terms of the cross-sectional associations,
the ﬁndings on the levels of chronic conditions,
comorbidity and multidrug prescribing do offer clinical
implications as outlined earlier. However, the implica-
tions of the associations between comorbidity and the
key drug deﬁnitions may be limited in this cross-
sectional design and these may be treated cautiously as
emergent ﬁndings. The chronic disease deﬁnitions were
also based on routinely collected registers from general
practices, which were and are part of a research network
dedicated to the collection of clinical data in actual con-
sultation. While these chronic disease registers may be
subject to variations in recording,32 the study analyses
provide the estimates of association in actual clinical
practice across 11 different sites.
The drug deﬁnitions were based on routinely coded
repeat prescriptions and over a 2-year time period repre-
sent an appropriate measure at the simpler but distinct
broad system category. Patients however will also have
been prescribed other drug categories outside of the
ﬁve main categories that we had selected and for other
less common conditions from the ones selected in the
study, which means these drug levels are a speciﬁc esti-
mate. The construction of our study deﬁned index or
‘alone’ groups (without the other ﬁve conditions) pro-
vided the relative multidrug level estimates to when the
index condition was comorbid with one of the other ﬁve
conditions. So the multidrug levels in the ‘alone’ group
provide an estimate of main drug system prescribing
without the associated condition (ie, for other indica-
tions) compared to levels when there is a clear
Table 4 Associations between vascular comorbidity groups and higher multidrug counts
Conditions
Multidrug number/10 000 population
Adjusted OR (95% CI)0 1 2 3 4 5
Vascular group only* 199 2373 4018 2547 773 89 1.0
Vascular group and COPD 85 677 2854 4207 2008 169 4.63 (3.8 to 5.7)
Prevalence ratio 0.43 0.29 0.71 1.65 2.60 1.90
Vascular group and OA 29 873 3493 3697 1557 349 3.01 (2.6 to 3.5)
Prevalence ratio 0.15 0.37 0.87 1.45 2.01 3.92
Vascular group and Depression 69 829 3733 3917 1359 92 3.22 (2.6 to 3.9)
Prevalence ratio 0.35 0.35 0.93 1.54 1.76 1.03
*Vascular group only is the reference group without COPD, OA or depression; prevalence ratio is comparing vascular comorbid group with
vascular group alone for each drug count category, adjusted for age, gender and deprivation and estimates are with the ‘outcome’ of higher
drug count (3–4 combined) compared with lower drug counts (2 or less).
COPD, chronic obstructive pulmonary disease; OA, osteoarthritis.
Table 5 Key drug treatments of non-vascular conditions in vascular comorbidity
Numbers (%)
Key drug treatments*
Unadjusted OR (95% CI) Adjusted OR (95% CI)No Yes
COPD without vascular comorbidity 123 (22) 937 (88) 1.0 1.0
COPD and vascular comorbidity 87 (19) 382 (81) 0.58 (0.43 to 0.78) 0.55 (0.40 to 0.75)
OA without vascular comorbidity 281 (16) 1440 (84) 1.0 1.0
OA and vascular comorbidity 117 (17) 568 (83) 0.95 (0.75 to 1.20) 0.82 (0.64 to 1.06)
Depression without vascular comorbidity 259 (16) 1378 (84) 1.0 1.0
Depression and vascular group 120 (28) 311 (72) 0.49 (0.38 to 0.62) 0.55 (0.42 to 0.73)
*Drug treatment for COPD, OA or depression, respectively, adjusted for age, gender and deprivation as measured by Index of Multiple
Deprivation.
COPD, chronic obstructive pulmonary disease; OA, osteoarthritis.
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comorbidity record. However, this is time deﬁned by a
2-year time window, so some misclassiﬁcation may be
possible and further research could explore how broad
system drug deﬁnitions capture the underlying and spe-
ciﬁc common diagnostic categories. Further research is
also required for the arguably more complex assimilation
of the range of deﬁned drug categories, other multimor-
bidity and to investigate speciﬁc effect of individual drug
categories. Most of these drugs, other than analgesia such
as anti-inﬂammatories, are not available over-the-counter
and are usually clinician prescribed. So it is possible that
common over-the-counter drugs, particularly in relation
to OA, may be an underestimate; however, the selection
of repeated prescribing would mitigate against such
underestimation. Finally, although a large scale study,
these general practices are drawn from one region of
England, and while this might limit generalisability, the
internal validity of the ﬁndings still remains.
In conclusion, our study ﬁndings show the links
between common chronic conditions, comorbidity and
associated multidrug prescribing. The key and distinct
ﬁnding is that the study shows that multidrug prescrib-
ing deﬁned by a range of selected but different systems
is high in chronic conditions and higher in comorbidity.
The common groups of vascular conditions are not the
only ones associated with their ‘own’ guideline driven
multidrug therapy, but the addition of non-vascular con-
ditions such as COPD, OA and depression adds to the
multidrugs burden in patients. The importance of these
ﬁndings, in addition to quantifying the scale, is whether
such multidrug therapy inﬂuences the quality of care for
each of the individual conditions. Our ﬁndings suggest
that the potential for suboptimal drug treatment as a
consequence is in line with other evidence33 but further
research is required to investigate the impact of disease
status, comorbidity, multidrug therapy on prospective
and long-term outcomes of clinical care.
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